MEMSCAP, S.A. (LON:0NYT)
London · Delayed Price · Currency is GBP · Price in EUR 4.145
+0.010 (0.24%)
At close: Aug 7, 2025
Achilles Therapeutics Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Revenue | 11.53 | 12.66 | 14.07 | 9.34 | 8.54 | 11.12 | Upgrade |
Revenue Growth (YoY) | -19.15% | -10.04% | 50.74% | 9.35% | -23.23% | -12.97% | Upgrade |
Cost of Revenue | 6.88 | 7.64 | 8.03 | 5.66 | 4.91 | 7.99 | Upgrade |
Gross Profit | 4.65 | 5.02 | 6.04 | 3.68 | 3.63 | 3.13 | Upgrade |
Selling, General & Admin | 2.41 | 2.42 | 2.16 | 1.93 | 1.81 | 2.14 | Upgrade |
Research & Development | 1.82 | 1.82 | 1.55 | 1.91 | 1.65 | 1.59 | Upgrade |
Other Operating Expenses | -0.39 | -0.39 | -0.14 | -0.4 | -0.47 | - | Upgrade |
Operating Expenses | 3.85 | 3.85 | 3.56 | 3.44 | 2.99 | 3.73 | Upgrade |
Operating Income | 0.81 | 1.17 | 2.48 | 0.24 | 0.64 | -0.59 | Upgrade |
Interest Expense | -0.34 | -0.17 | -0.15 | -0.14 | -0.14 | -0.15 | Upgrade |
Interest & Investment Income | 0.12 | 0.23 | 0.08 | 0.01 | 0.04 | 0.04 | Upgrade |
Currency Exchange Gain (Loss) | 0.17 | 0.17 | -0.23 | 0.14 | 0.06 | -0.06 | Upgrade |
Other Non Operating Income (Expenses) | - | - | - | - | -0.06 | - | Upgrade |
EBT Excluding Unusual Items | 0.76 | 1.4 | 2.17 | 0.24 | 0.53 | -0.77 | Upgrade |
Other Unusual Items | - | - | - | - | - | 0.33 | Upgrade |
Pretax Income | 0.76 | 1.4 | 2.17 | 0.24 | 0.53 | -0.45 | Upgrade |
Income Tax Expense | 0.01 | 0.02 | 0.03 | 0.09 | 0.06 | 0.1 | Upgrade |
Earnings From Continuing Operations | 0.75 | 1.37 | 2.14 | 0.15 | 0.48 | -0.55 | Upgrade |
Earnings From Discontinued Operations | - | - | - | 0.9 | -0.81 | - | Upgrade |
Net Income | 0.75 | 1.37 | 2.14 | 1.05 | -0.33 | -0.55 | Upgrade |
Net Income to Common | 0.75 | 1.37 | 2.14 | 1.05 | -0.33 | -0.55 | Upgrade |
Net Income Growth | -62.71% | -35.79% | 104.20% | - | - | - | Upgrade |
Shares Outstanding (Basic) | - | 8 | 7 | 7 | 7 | 7 | Upgrade |
Shares Outstanding (Diluted) | - | 8 | 8 | 7 | 7 | 7 | Upgrade |
Shares Change (YoY) | - | -0.35% | 3.24% | -0.03% | 0.07% | 0.11% | Upgrade |
EPS (Basic) | - | 0.18 | 0.29 | 0.14 | -0.04 | -0.07 | Upgrade |
EPS (Diluted) | - | 0.18 | 0.28 | 0.14 | -0.04 | -0.07 | Upgrade |
EPS Growth | - | -35.61% | 98.25% | - | - | - | Upgrade |
Free Cash Flow | - | 0.34 | 1.41 | -0.16 | 1.57 | 0.97 | Upgrade |
Free Cash Flow Per Share | - | 0.04 | 0.18 | -0.02 | 0.21 | 0.13 | Upgrade |
Gross Margin | 40.36% | 39.67% | 42.92% | 39.38% | 42.48% | 28.16% | Upgrade |
Operating Margin | 7.00% | 9.26% | 17.61% | 2.54% | 7.45% | -5.34% | Upgrade |
Profit Margin | 6.46% | 10.85% | 15.21% | 11.22% | -3.84% | -4.90% | Upgrade |
Free Cash Flow Margin | - | 2.70% | 9.99% | -1.73% | 18.38% | 8.68% | Upgrade |
EBITDA | 1.59 | 1.96 | 2.74 | 0.8 | 1.11 | 0.1 | Upgrade |
EBITDA Margin | 13.80% | 15.50% | 19.48% | 8.53% | 12.97% | 0.94% | Upgrade |
D&A For EBITDA | 0.78 | 0.79 | 0.26 | 0.56 | 0.47 | 0.7 | Upgrade |
EBIT | 0.81 | 1.17 | 2.48 | 0.24 | 0.64 | -0.59 | Upgrade |
EBIT Margin | 7.00% | 9.26% | 17.61% | 2.54% | 7.45% | -5.34% | Upgrade |
Effective Tax Rate | 1.71% | 1.72% | 1.52% | 37.86% | 10.67% | - | Upgrade |
Revenue as Reported | 12.66 | 12.66 | 14.07 | 9.34 | 8.54 | 11.12 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.